Eminent doc: Media censored COVID-19 early treatment options that could have reduced fatalities by 85%. Dr. Peter McCullough also explained that given an 80% level of herd immunity, broad vaccination has ‘no scientific, clinical or safety rationale.’ Thu Apr 8, 2021 ... “People who develop COVID have complete and durable immunity. And (that’s) a very important principle: complete and durable. You can't beat natural immunity. You can't vaccinate on top of it and make it better. There's no scientific, clinical or safety rationale for ever vaccinating a COVID-recovered patient. There's no rationale for ever testing a COVID-recovered patient,” he continued... “My wife and I are COVID-recovered. Why do we go through the testing outside? There's absolutely no rationale (for such testing).” ... “There's plenty of COVID-recovered patients. Let them forgo the vaccine and let people who are clamoring for it get it. But at 80 percent herd immunity, in the vaccine trials fewer than one percent … in the placebo actually get COVID. Fewer than one percent. The vaccine is going to have a one percent public health impact. That's what the data says. It's not going to save us, we’re already 80 percent herd immune,” he said.
Britain Will Achieve Herd Immunity on Monday. April 8, 2021.
“The most likely duration of immunity to a respiratory virus like SARS CoV-2 is multiple years. Why do I say that? We actually have the data for a virus that swept through parts of the world seventeen years ago called SARS, and remember SARS CoV-2 is 80% similar to SARS, so I think that’s the best comparison that anyone can provide.
“The evidence is clear: These very clever cellular immunologists studied all the people they could get hold of who had survived SARS 17 years ago. They took a blood sample, and they tested whether they responded or not to the original SARS and they all did; they all had perfectly normal, robust T cell memory. They were actually also protected against SARS CoV-2, because they’re so similar; it’s cross immunity.
“So, I would say the best data that exists is that immunity should be robust for at least 17 years. I think it’s entirely possible that it is lifelong. The style of the responses of these people’s T cells were the same as if you’ve been vaccinated and then you come back years later to see if that immunity has been retained. So I think the evidence is really strong that the duration of immunity will be multiple years, and possibly lifelong.”
How Broad is Covid Immunity? March 2021
How Worried Should We Be About the Variants? March 2021. by Dr Michael Yeadon, Scientific Board member of Panda, Expert in Allergy & Respiratory (A&R) Therapeutic/PhD in Biochemistry and Toxicology, Former Chief Scientific Officer at Pfizer A&R unit/CEO and Founder of Ziarco, 25 years experience in Drug Discovery/40 Full Papers/63 Abstracts/two Books/six Patents and Marc Girardot, Member of Panda, Senior Advisor in Biotech & Automotive/INSEAD MBA, Advisor to an anti-Cancer therapeutic vaccine company/Ex-Global Lead of Cisco’s IBSG Automotive, 30 years of experience in Industry, High Tech and Biotech/two Patents. Snippets include:
To date, no robust scientific evidence proves that any of the variants identified are more transmissible or deadly than the original... Prior immunity gained from the original SARS-CoV-2 should work perfectly well against any new ‘mutant variant’, given the 99.7% sequence similarity.... mRNA vaccines currently used for vaccination – Pfizer-BioNTech or Moderna – present the immune system with a large repertoire of targets, if not quite as large as a natural immune response. This is even more true of more traditional vaccines – Russia’s Sputnik and China’s Sinovac – which present an even wider repertoire. ... Many seem to have benefited from a form of immunity even though they had never met the actual virus, nor been vaccinated. These have gained their immunity from past epidemics and make up the large contingent of asymptomatics. The Tübingen University Hospital near Stuttgart, Germany found as much as 81% of its samples were carrying pre-existing specific T cells. Most likely, past common cold coronaviruses have – in effect – played an immunisation role against SARS-CoV-2. The same immunological mechanism has been proven to exist for influenza also... Some are advocating the vaccination of people who have recovered from COVID-19. Natural immunisation being the ultimate form of vaccination, we see absolutely no scientific nor medical justification for such a procedure. Even past infections by other forms of common cold coronaviruses have been found to protect from SARS-CoV-2. Injecting a vaccine should never be considered a trivial event. The decision should be based on a well thought out risk-benefit analysis... The evidence above supports that immunity evasion – though a theoretical possibility – is very unlikely. Mutant variants, emerging overseas or domestically, are an inevitable biological reality once a virus is in the population. Closing international borders will not stop new mutations of the SARS-CoV-2 virus circulating in the population. It is a futile endeavour with no scientific basis ... Although vaccines could be helpful for patients with mildly deficient immune systems, they would most likely not save very old patients with advanced immune senescence. Thus overconfidence in vaccine effectiveness for the very old could be a major risk, and mitigation treatments and immune boosting strategies should instead be contemplated.
Amish community in Pennsylvania becomes first in US to achieve herd immunity after reopening churches led to 90% of households being infected with the virus last year March 2021
- The Plain community in Lancaster County has become the 'first to achieve herd immunity,' according to a local administrator of a medical center in the area
- Allen Hoover of the Parochial Medical Center said that 90% of households became infected with virus when they resumed church services late last spring
- As Hoover observed, faith in herd immunity prompted members of community to relax on key mitigation efforts such as masking and social distancing
Immunity & COVID-19 - British Society for Immunology February 2021
Israeli study boosts belief post-COVID immunity stays when antibodies fade Massive immune response witnessed when small cohort of previously infected people get 1st COVID-19 vaccine dose, indicating they are well ahead of the game, Bar-Ilan team says. By Nathan Jeffay February 2021 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.6.2100096
COVID 19 Immunity Research. You could be IMMUNE to COVID. Medicine with Dr. Moran. September 2020.
The Innate Immune System webinar and live Q&A with Dr. Zach Bush, Dr. Cindy Fallon, Dr. John Gildea, Dr. Lee Cowden and Dr. Peter Cummings. Jan 18, 2021. A break down of the intricacies and beauty of how our innate immune system functions and flows, unearthed empowering facts on the latest scientific findings on the virome, historical framing of germ warfare and how it applies to today’s mindset toward the pandemic and so much more from top experts across various fields within the human health realm. View the full feature on the Innate Immune System along with resources mentioned in this webinar: https://zachbushmd.com/innate-immune-... If you are looking to dive deeper and prioritize your health, sign up for the Intrinsic Health Series: https://www.intrinsichealthseries.com Knowledge Base : SLEEP module: View the webinar replay, video and blog on how critical sleep is to your immune health: https://zachbushmd.com/knowledge-sleep/
Human immune system has a 99.74% success rate against COVID19 Alex Jones with Del Bigtree, August 2020
How ‘killer’ T cells could boost COVID immunity in face of new variants. In the race against emerging coronavirus variants, researchers are looking beyond antibodies for clues to lasting protection from COVID-19. February 2021.
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Quan-Xin Long, Xiao-Jun Tang, Qiu-Lin Shi, Qin Li, Hai-Jun Deng, Jun Yuan, Jie-Li Hu, Wei Xu, Yong Zhang, Fa-Jin Lv, Kun Su, Fan Zhang, Jiang Gong, Bo Wu, Xia-Mao Liu, Jin-Jing Li, Jing-Fu Qiu, Juan Chen & Ai-Long Huang in Nature Medicine
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Jennifer M. Dan, Jose Mateus, Yu Kato1, Kathryn M. Hastie, Esther Dawen Yu, Caterina E. Faliti, Alba Grifoni, Sydney I. Ramirez, Sonya Haupt, April Frazier, Catherine Nakao, Vamseedhar Rayaprolu, Stephen A. Rawlings, Bjoern Peters, Florian Krammer, Viviana Simon, Erica Ollmann Saphire, Davey M. Smith, https://doi.org/10.1136/bmj.m3563Daniela Weiskopf, Alessandro Sette, Shane Crotty in Science Feb 2021:
Immune system’s T cells can mount attacks against many coronavirus targets — even on new variants, LJI says By La Jolla Institute for Immunology. January 2021. A new study led by scientists at the La Jolla Institute for Immunology suggests that T cells try to fight SARS-CoV-2, the coronavirus that causes COVID-19, by targeting a broad range of sites on the virus. By attacking the virus from many angles, the body has the tools to potentially recognize different SARS-CoV-2 variants.
Covid-19: Do many people have pre-existing immunity? British Medical Journal 2020; 370 doi: September 2020 https://doi.org/10.1136/bmj.m3563
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Dec.2020. Sheila F. Lumley, B.M., B.Ch., Denise O’Donnell, B.Sc., Nicole E. Stoesser, M.B., B.S., D.Phil., Philippa C. Matthews, F.R.C.P., D.Phil., Alison Howarth, Ph.D., Stephanie B. Hatch, Ph.D., Brian D. Marsden, D.Phil., Stuart Cox, Tim James, Ph.D., Fiona Warren, B.Sc., Liam J. Peck, D.Phil., Thomas G. Ritter, B.A., Zoe de Toledo, M.Sc., Laura Warren, David Axten, B.A., Richard J. Cornall, M.D., D.Phil., E. Yvonne Jones, D.Phil., David I. Stuart, Ph.D., Gavin Screaton, B.M., B.Ch., D.Phil., Daniel Ebner, B.Sc., Sarah Hoosdally, Ph.D., Meera Chand, M.B., B.S., Derrick W. Crook, F.R.C.Path., Anne-Marie O’Donnell, M.B., B.S., Christopher P. Conlon, M.D., Koen B. Pouwels, Ph.D., A. Sarah Walker, Ph.D., Tim E.A. Peto, F.R.C.P., Susan Hopkins, F.R.C.P., Timothy M. Walker, M.B., B.S., D.Phil. Katie Jeffery, F.R.C.Path., Ph.D., and David W. Eyre, B.M., B.Ch., D.Phil. for the Oxford University Hospitals Staff Testing Group*
Vaccines can sometimes cause the disease they are supposed to eradicate: the world is currently facing an increasing spread of type 2 circulating vaccine-derived poliovirus outbreaks across parts of Africa, Southeast Asia and the Middle East. March 2020
Do some people have protection against the coronavirus? By Dr. Sanjay Gupta and Andrea Kane, CNN. August 2, 2020. Immunity is comprised of not just antibodies but various T cells -- cells that act as "memory" to foreign invaders. The good news, when it comes to this coronavirus, is that people who have never had any exposure to this virus may actually have some T-cell reactivity. A study that looked at blood that was collected between 2015 and 2018, well before the first Covid-19 infection, found some people had T cells that reacted to the virus.
We could ‘beat’ COVID-19 before a vaccine is ready By Alex Berenson August 25, 2020
Herd Immunity May Be Slowing Spread in U.S., As Study Finds 40 Percent Community Infection Provides Protection By Aristos Georgiou On 8/14/20
New York’s latest COVID antibody survey shows a rise in the Bronx and minority communities June 16, 2020 By Dana Schulz
Johns Hopkins Doctor Thinks COVID Will Be Largely Gone By April, Half of U.S. Has Herd Immunity By Katherine Fung On 2/19/21
Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021 Extrapolating from antibody testing on blood donors, the researchers found antibody levels of 63% in Eastern Cape province (EC), 46% in Free State (FS), 52% in KwaZulu Natal (ZN) and 32% in Northern Cape (NC). These figures were between 15 and 22 times higher than the percentage of the population that had tested positive for the virus to date.
... there is nothing unusual about a COVID-19 epidemic going into spontaneous decline, even with antibody prevalence much lower than in South Africa. Places with few restrictions such as Sweden, Florida and South Dakota have also seen spikes fall almost as quickly as they have risen, and at much lower antibody levels – and in the middle of winter, too.